Medical Devices

Request for TOC Request for Sample
BUY NOW

Middle East and Africa Prostate Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Medical Devices | Published Report | Mar 2021 | MEA | 350 Pages | No of Tables: 123 | No of Figures: 55

Report Description

Middle East and Africa Prostate Cancer Diagnostics Market, By Product Type (Instruments, Reagents & Consumables and Accessories), Diagnostics Type (Preliminary Screening Tests, Confirmatory Tests), Age Group (Adult, Pediatric and Geriatrics), Type (Prostatic Adenocarcinoma, Small Cell Carcinoma and Others), Stage (Localized Prostate Cancer, Recurrent/Advanced Prostate Cancer and Castration-Resistant Prostate Cancer (Metastatic and Non-Metastatic)), Sample Type (Blood, Tissue, Urine and Others), End User (Independent Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Retail Sales), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel & Rest of Middle East and Africa) Industry Trends and Forecast to 2028     

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights: Middle East and Africa Prostate Cancer Diagnostics Market

The prostate cancer diagnostics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 12.9% in the forecast period of 2021 to 2028 and is expected to reach USD 320.40 million by 2028. Increasing focus on the disease burden and increasing awareness regarding the disease are the major drivers which are propelling the prostate cancer diagnostics market in the forecast period.

The prostate cancer begins when the cells in the prostate gland started to grow at an abnormal pace and the condition is known to be prostate cancer. The prostate is a gland found only in males. It makes some of the fluid that is part of semen. The prostate cancer diagnostics is a technique of detection of cancer mainly in the early stage to conduct the future treatment approach which can increase the survival rate.

The development of prostate cancer is closely linked with the age, with the increasing geriatric population, there is the significant increase in the incidence for prostate cancer. This will increase the demand for the diagnostics product for the detection of the disease and is expected to act as a driver for the prostate cancer diagnostics market. The PSA testing is one of the primary tests that are used for prostate cancer detection. However, the contradictions between the government and medical services provider for using PSA and related test is expected to restraint the prostate cancer diagnostics market. The market have a huge potential to grow and with the entry of new market players trying to enter market using business expansion via distribution agreements and have invested towards the prostate cancer diagnosis is expected to increase the market size and will act as opportunity for the prostate cancer diagnostics market. The barrier related with conducting the cancer diagnostics test may affect the life of the population and this is one of the most difficult part to overcome with respect to the low income countries, thus this is affecting the diagnostics community and acting as a challenge for the prostate cancer diagnostics market.  

The prostate cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the prostate cancer diagnostics market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Get Exclusive Sample Copy of this Report Here

Prostate Cancer Diagnostics Market Scope and Market Size

The prostate cancer diagnostics market is categorized into eight notable segments which are based on the product type, diagnostics type, age group, type, stage, sample type, end users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of product type, the prostate cancer diagnostics market is segmented into instruments, reagents & consumables and accessories. In 2021, reagents & consumables segment is dominating in the prostate cancer diagnostics market as it includes the PSA testing products which is the primary test recommended for preliminary testing.
  • On the basis of diagnostics type, the prostate cancer diagnostics market is segmented into preliminary screening tests and confirmatory tests. In 2021, preliminary screening tests segment is dominating in the prostate cancer diagnostics market as the number of preliminary tests surpass the number of confirmatory tests by significant percentage.  
  • On the basis of age group, the prostate cancer diagnostics market is segmented into adult, pediatric and geriatrics. In 2021, geriatrics segment is dominating in the prostate cancer diagnostics market as around 60% of cases are diagnosed in men over 65 year of age.
  • On the basis of type, the prostate cancer diagnostics market is segmented into prostatic adenocarcinoma, small cell carcinoma and others. In 2021, prostatic adenocarcinoma segment dominates the prostate cancer diagnostics market because more than 95 percent of prostate cancers are adenocarcinomas which develop in the gland cells and line of the prostate gland.
  • On the basis of stage, the prostate cancer diagnostics market is segmented into localized prostate cancer, recurrent/advanced prostate cancer and castration-resistant prostate cancer (metastatic and non-metastatic). In 2021, localized prostate cancer segment dominates the prostate cancer diagnostics market as approximately 80 percent to 85 percent of all prostate cancers are detected in the local or regional stages which represent stages I, II and III.
  • On the basis of sample type, the prostate cancer diagnostics market is segmented into blood, tissue, urine and others. In 2021, blood segment is dominating the prostate cancer diagnostics market as blood is the primary sample for the most common preliminary test that is PSA test and due to easy availability of blood, less complex procedure of blood sample collection doesn’t take much time which is expected to dominate the prostate cancer diagnostics market.  
  • On the basis of end users, the prostate cancer diagnostics market is segmented into independent diagnostic laboratories, hospitals, cancer research institutes, clinics, ambulatory surgical centers and others. In 2021, independent diagnostic laboratories segment is dominating the prostate cancer diagnostics market as the segment is specialized in conducting various prostate cancer diagnostics.
  • On the basis of distribution channel, the prostate cancer diagnostics market is segmented into direct tender and retail sales. In 2021, direct tender segment dominates the prostate cancer diagnostics market as they are the primary source of procurement of reagents, consumables, devices and accessories by healthcare organizations and diagnostic labs.

Prostate Cancer Diagnostics Market Country Level Analysis

The prostate cancer diagnostics market is analysed and market size information is provided by the country, product type, diagnostics type, age group, type, stage, sample type, end users and distribution channel as referenced above.

The countries covered in the prostate cancer diagnostics market report are the South Africa, Saudi Arabia, UAE, Egypt, Israel & Rest of Middle East and Africa.

South Africa is expected to grow in the forecast period of 2021 to 2028 due to increasing focus on prostate cancer diagnostics products and rising awareness about it.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Strategic Initiatives by manufactures is Creating New Opportunities for Players in the Prostate Cancer Diagnostics Market 

The prostate cancer diagnostics market also provides you with detailed market analysis for every country growth in prostate cancer diagnostics product sales, impact of advancement in the prostate cancer diagnostics and changes in regulatory scenarios with their support for the prostate cancer diagnostics market. The data is available for historic period 2010 to 2019. 

Competitive Landscape and Prostate Cancer Diagnostics Market Share Analysis

The prostate cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to prostate cancer diagnostics market.  

The major companies providing prostate cancer diagnostics market are F. Hoffmann-La Roche Ltd, ACON Laboratories, Inc., HUMASIS, Teco Diagnostics, Hologic Inc., Accuquik Test Kits, MDxHealthcare, Abbott, Siemens Healthcare GmbH, OPKO Health Inc., Myraid Genetics, Inc., DiaSorin S.p.A, Beckman Coulter, Inc. (a subsidiary of Danaher), Genomic Health, Inc. (a subsidiary of Exact Sciences Corporation), bioMérieux SA, Metamark Genetics, Inc., Prostatype Genomics, Fujirebio, Proteomedix, Eurolyser Diagnostica GmbH among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the prostate cancer diagnostics market.

For instance,  

  • In January 2021, Hologic Inc. announced that they have agreed to acquire SOMATEX, Inc., for USD 64 million. This company is the provider of Biomarkers for cancer. After the complete acquisition, Hologic Inc. will take a jump start in global oncology biomarker and will expand the company product portfolio for cancer patients and will add up to the company’s future sales and revenue.
  • In August 2020, HUMASIS announced that they have passed the preliminary examination for listing by the Korea Exchange last month after undergoing a technical evaluation process by a professional evaluation agency in November last year and is soon to be get n approval for the listing in Korean stock exchange. This will be an achievement for the company and will boost the company in future business expansion and business strategies.

Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the prostate cancer diagnostics market which also provides the benefit for organisation to improve their offering for prostate cancer diagnostics market.   

 

 


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USERS COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 EPIDEMIOLOGY

5 COMPARATIVE ANALYSIS WITH PARENT MARKET

6 REGULATORY FRAMEWORK: MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET

6.1 REGULATORY SCENARIO IN THE U.S.

6.2 REGULATORY SCENARIO IN EUROPEAN UNION

6.3 REGULATORY SCENARIO IN JAPAN

6.4 REGULATORY SCENARIO IN CHINA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF PROSTATE CANCER

7.1.2 INCREASE RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTIC

7.1.3 INCREASE IN GERIATRIC POPULATION

7.1.4 LAUNCH OF NEW PRODUCTS FOR PROSTATE CANCER DIAGNOSTIC

7.1.5 DISEASE CAUSING PROSTATE CANCER

7.2 RESTRAINTS

7.2.1 CONTROVERSY RELATED TO PSA TESTING

7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE

7.2.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS

7.3 OPPORTUNITIES

7.3.1 RISING INVESTMENT AND FUNDING BY EMERGING PLAYERS

7.3.2 REIMBURSEMENT POLICY FOR PROSTATE CANCER DIAGNOSIS

7.3.3 GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS

7.3.4 RISING SURVIVAL RATE DUE TO EARLY DIAGNOSIS OF PROSTATE CANCER

7.4 CHALLENGES

7.4.1 STRINGENT REGULATORY REQUIREMENT FOR DIAGNOSTIC PRODUCTS

7.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTICS TESTS

7.4.3 INACCURATE DIAGNOSIS RESULTS

8 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET

8.1 IMPACT ON PRICE

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC DECISION BY MANUFACTURERS MADE DURING COVID-19 PANDEMIC

8.5 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19

8.6 CONCLUSION

9 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE

9.1 OVERVIEW

9.2 REAGENTS & CONSUMABLES

9.3 INSTRUMENTS

9.4 ACCESSORIES

10 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE

10.1 OVERVIEW

10.2 PRELIMINARY SCREENING TESTS

10.2.1 PROSTATE-SPECIFIC ANTIGEN (PSA) TEST

10.2.2 DIGITAL RECTAL EXAM (DRE) TEST

10.3 CONFIRMATORY TESTS

10.3.1 PCA3 TEST

10.3.2 BIOPSY

10.3.3 IMAGING TESTS

10.3.3.1 ULTRASOUND

10.3.3.2 MAGNETIC RESONANCE IMAGING (MRI)

10.3.3.2.1 MULTIPARAMETRIC MRI

10.3.3.2.2 MRI FUSION-GUIDED PROSTATE BIOPSY

10.3.3.3 CT SCAN

10.3.3.4 BONE SCAN

10.3.3.5 PET/CT SCAN

10.3.4 BIOMARKER

10.3.4.1 RNA BIOMARKERS

10.3.4.2 DNA BIOMARKERS

10.3.4.3 PROTEIN BIOMARKERS

11 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE

11.1 OVERVIEW

11.2 PROSTATIC ADENOCARCINOMA

11.3 SMALL CELL CARCINOMA

11.4 OTHERS

12 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP

12.1 OVERVIEW

12.2 GERIATRICS

12.3 ADULT

12.4 PEDIATRIC

13 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE

13.1 OVERVIEW

13.2 LOCALIZED PROSTATE CANCER

13.3 RECURRENT/ADVANCED PROSTATE CANCER

13.4 CASTRATION-RESISTANT PROSTATE CANCER (METASTATIC AND NON-METASTATIC)

14 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE

14.1 OVERVIEW

14.2 BLOOD

14.3 TISSUE

14.4 URINE

14.5 OTHERS

15 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS

15.1 OVERVIEW

15.2 INDEPENDENT DIAGNOSTIC LABORATORIES

15.3 HOSPITALS

15.4 CLINICS

15.5 AMBULATORY SURGICAL CENTERS

15.6 CANCER RESEARCH INSTITUTES

15.7 OTHERS

16 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 DIRECT TENDER

16.3 RETAIL SALES

17 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY

17.1 MIDDLE EAST & AFRICA

17.1.1 SOUTH AFRICA

17.1.2 SAUDI ARABIA

17.1.3 UAE

17.1.4 ISRAEL

17.1.5 EGYPT

17.1.6 REST OF MIDDLE EAST & AFRICA

18 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

19 SWOT

20 COMPANY PROFILE

20.1 F. HOFFMANN-LA ROCHE LTD

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 COMPANY SHARE ANALYSIS

20.1.4 PRODUCT PORTFOLI0

20.1.5 RECENT DEVELOPMENTS

20.2 ABBOTT

20.2.1 COMPANY SNAPSHOT

20.2.2 REVENUE ANALYSIS

20.2.3 COMPANY SHARE ANALYSIS

20.2.4 PRODUCT PORTFOLIO

20.2.5 RECENT DEVELOPMENTS

20.3 SIEMENS HEALTHCARE GMBH

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 COMPANY SHARE ANALYSIS

20.3.4 PRODUCT PORTFOLIO

20.3.5 RECENT DEVELOPMENTS

20.4 OPKO HEALTH INC.

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 COMPANY SHARE ANALYSIS

20.4.4 PRODUCT PORTFOLIO

20.4.5 RECENT DEVELOPMENTS

20.5 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER)

20.5.1 COMPANY SNAPSHOT

20.5.2 REVENUE ANALYSIS

20.5.3 COMPANY SHARE ANALYSIS

20.5.4 PRODUCT PORTFOLIO

20.5.5 RECENT DEVELOPMENTS

20.6 ACCUQUIK TEST KITS

20.6.1 COMPANY SNAPSHOT

20.6.2 PRODUCT PORTFOLIO

20.6.3 RECENT DEVELOPMENT

20.7 ACON LABORATORIES INC.

20.7.1 COMPANY SNAPSHOT

20.7.2 PRODUCT PORTFOLIO

20.7.3 RECENT DEVELOPMENTS

20.8 BIOMERIEUX SA

20.8.1 COMPANY SNAPSHOT

20.8.2 REVENUE ANALYSIS

20.8.3 PRODUCT PORTFOLIO

20.8.4 RECENT DEVELOPMENT

20.9 DIASORIN S.P.A

20.9.1 COMPANY SNAPSHOT

20.9.2 REVENUE ANALYSIS

20.9.3 PRODUCT PORTFOLI0

20.9.4 RECENT DEVELOPMENTS

20.1 EUROLYSER DIAGNOSTICA GMBH

20.10.1 COMPANY SNAPSHOT

20.10.2 PRODUCT PORTFOLIO

20.10.3 RECENT DEVELOPMENT

20.11 FUJIREBIO

20.11.1 COMPANY SNAPSHOT

20.11.2 PRODUCT PORTFOLI

20.11.3 RECENT DEVELOPMENTS

20.12 GENOMIC HEALTH, INC., (A SUBSIDIARY OF EXACT SCIENCES CORPORATION)

20.12.1 COMPANY SNAPSHOT

20.12.2 REVENUE ANALYSIS

20.12.3 PRODUCT PORTFOLIO

20.12.4 RECENT DEVELOPMENTS

20.13 HOLOGIC, INC.

20.13.1 COMPANY SNAPSHOT

20.13.2 REVENUE ANALYSIS

20.13.3 PRODUCT PORTFOLIO

20.13.4 RECENT DEVELOPMENTS

20.14 HUMASIS

20.14.1 COMPANY SNAPSHOT

20.14.2 PRODUCT PORTFOLIO

20.14.3 RECENT DEVELOPMENTS

20.15 MDXHEALTHCARE

20.15.1 COMPANY SNAPSHOT

20.15.2 REVENUE ANALYSIS

20.15.3 PRODUCT PORTFOLIO

20.15.4 RECENT DEVELOPMENTS

20.16 METAMARK GENETICS, INC.

20.16.1 COMPANY SNAPSHOT

20.16.2 PRODUCT PORTFOLI0

20.16.3 RECENT DEVELOPMENTS

20.17 MYRAID GENETICS, INC.

20.17.1 COMPANY SNAPSHOT

20.17.2 REVENUE ANALYSIS

20.17.3 PRODUCT PORTFOLIO

20.17.4 RECENT DEVELOPMENTS

20.18 PROSTATYPE GENOMICS

20.18.1 COMPANY SNAPSHOT

20.18.2 REVENUE ANALYSIS

20.18.3 PRODUCT PORTFOLIO

20.18.4 RECENT DEVELOPMENTS

20.19 PROTEOMEDIX

20.19.1 COMPANY SNAPSHOT

20.19.2 PRODUCT PORTFOLIO

20.19.3 RECENT DEVELOPMENTS

20.2 TECO DIAGNOSTICS

20.20.1 COMPANY SNAPSHOT

20.20.2 PRODUCT PORTFOLIO

20.20.3 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

List of Table

LIST OF TABLES

TABLE 1 CATEGORIZATION UNDER THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS (CLIA '88) OF 1988

TABLE 2 AGE AND PROBABILITY OF DEVELOPING PROSTATE CANCER

TABLE 3 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 2019-2028 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 2019-2028 (UNITS)

TABLE 5 MIDDLE EAST AND AFRICA REAGENTS & CONSUMABLES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA INSTRUMENTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA ACCESSORIES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA CONFIRMATORY TESTSIN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA PROSTATIC ADENOCARCINOMAS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION

TABLE 13 MIDDLE EAST AND AFRICA SMALL CELL CARCINOMA IN PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA OTHERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA GERIATRICS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA SEVERE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA SEVERE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA LOCALIZED PROSTATE CANCER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA RECURRENT/ADVANCED PROSTATE CANCER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA CASTRATION-RESISTANT PROSTATE CANCER (METASTATIC AND NON-METASTATIC) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA BLOOD IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA TISSUE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA URINE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA OTHERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA INDEPENDENT DIAGNOSTIC LABORATORIES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA HOSPITALS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA CLINICS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA CANCER RESEARCH INSTITUTES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA DIRECT TENDER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA HOSPITALS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 41 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 46 MIDDLE EAST & AFRICA BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 47 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 53 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 54 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 55 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 56 SOUTH AFRICA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 57 SOUTH AFRICA CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 58 SOUTH AFRICA IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 59 SOUTH AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 60 SOUTH AFRICA BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 61 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 62 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 63 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 64 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 65 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 66 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 67 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 68 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 69 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 70 SAUDI ARABIA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 71 SAUDI ARABIA CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 72 SAUDI ARABIA IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 73 SAUDI ARABIA MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 74 SAUDI ARABIA BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 75 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 76 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 78 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 79 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 80 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 81 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 82 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 83 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 84 UAE PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 85 UAE CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 86 UAE IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 87 UAE MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 88 UAE BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 89 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 90 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 91 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 92 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 93 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 94 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 95 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 96 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 97 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 98 ISRAEL PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 99 ISRAEL CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 100 ISRAEL IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 101 ISRAEL MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 102 ISRAEL BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 103 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 104 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 105 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 106 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 107 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 108 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 109 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 110 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)

TABLE 111 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 112 EGYPT PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 113 EGYPT CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 114 EGYPT IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 115 EGYPT MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 116 EGYPT BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)

TABLE 117 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)

TABLE 118 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 119 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 120 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)

TABLE 121 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)

TABLE 122 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 123 REST OF MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

 

List of Figure

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET : DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: MARKET END USERS COVERAGE GRID

FIGURE 10 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF PROSTATE CANCER AND INCREASED RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTICS ARE DRIVING THE MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET IN 2021 & 2028

FIGURE 14 REGULATORY FRAMEWORK FOR APPROVAL PROCESS IN CHINA

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET

FIGURE 16 ESTIMATED INCIDENCE CASES OF PROSTATE CANCER, ALL AGES

FIGURE 17 GERIATRIC POPULATION IN THE EUROPEAN REGION

FIGURE 18 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2020

FIGURE 19 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2020-2028 (USD MILLION)

FIGURE 20 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2021-2028)

FIGURE 21 PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 22 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE, 2020

FIGURE 23 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE 2020-2028 (USD MILLION)

FIGURE 24 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE, CAGR (2021-2028)

FIGURE 25 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE, LIFELINE CURVE

FIGURE 26 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020

FIGURE 27 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020-2028 (USD MILLION)

FIGURE 28 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2020-2028)

FIGURE 29 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 30 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2020

FIGURE 31 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP , 2020-2028 (USD MILLION)

FIGURE 32 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2021-2028)

FIGURE 33 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 34 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, 2020

FIGURE 35 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, 2020-2028 (USD MILLION)

FIGURE 36 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, CAGR (2021-2028)

FIGURE 37 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, LIFELINE CURVE

FIGURE 38 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2020

FIGURE 39 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2020-2028 (USD MILLION)

FIGURE 40 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, CAGR (2021-2028)

FIGURE 41 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, LIFELINE CURVE

FIGURE 42 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, 2020

FIGURE 43 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, 2020-2028 (USD MILLION)

FIGURE 44 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, CAGR (2021-2028)

FIGURE 45 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, LIFELINE CURVE

FIGURE 46 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 47 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 48 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 49 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION, LIFELINE CURVE

FIGURE 50 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2020)

FIGURE 51 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020)

FIGURE 52 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)

FIGURE 53 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 54 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2021-2028)

FIGURE 55 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)

 

View Infographics

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET : DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: MARKET END USERS COVERAGE GRID

FIGURE 10 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF PROSTATE CANCER AND INCREASED RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTICS ARE DRIVING THE MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET IN 2021 & 2028

FIGURE 14 REGULATORY FRAMEWORK FOR APPROVAL PROCESS IN CHINA

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET

FIGURE 16 ESTIMATED INCIDENCE CASES OF PROSTATE CANCER, ALL AGES

FIGURE 17 GERIATRIC POPULATION IN THE EUROPEAN REGION

FIGURE 18 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2020

FIGURE 19 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2020-2028 (USD MILLION)

FIGURE 20 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2021-2028)

FIGURE 21 PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 22 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE, 2020

FIGURE 23 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE 2020-2028 (USD MILLION)

FIGURE 24 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE, CAGR (2021-2028)

FIGURE 25 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE, LIFELINE CURVE

FIGURE 26 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020

FIGURE 27 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020-2028 (USD MILLION)

FIGURE 28 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2020-2028)

FIGURE 29 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 30 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2020

FIGURE 31 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP , 2020-2028 (USD MILLION)

FIGURE 32 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2021-2028)

FIGURE 33 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 34 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, 2020

FIGURE 35 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, 2020-2028 (USD MILLION)

FIGURE 36 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, CAGR (2021-2028)

FIGURE 37 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, LIFELINE CURVE

FIGURE 38 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2020

FIGURE 39 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2020-2028 (USD MILLION)

FIGURE 40 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, CAGR (2021-2028)

FIGURE 41 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, LIFELINE CURVE

FIGURE 42 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, 2020

FIGURE 43 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, 2020-2028 (USD MILLION)

FIGURE 44 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, CAGR (2021-2028)

FIGURE 45 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, LIFELINE CURVE

FIGURE 46 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 47 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 48 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 49 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION, LIFELINE CURVE

FIGURE 50 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2020)

FIGURE 51 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020)

FIGURE 52 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)

FIGURE 53 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 54 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2021-2028)

FIGURE 55 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 8500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19